The first genome-wide association study of an infectious disease, conducted by an international group of researchers through the Center for HIV/AIDS Vaccine Immunology (CHAVI), has yielded a new understanding of why some people can suppress virus levels following HIV infection. The clearer picture of host responses to the virus achieved through this examination of genomes could lead to improved HIV therapies and provides new targets for vaccine developers, says Elias A. Zerhouni, M.D., director of the National Institutes of Health (NIH). CHAVI, which is led by Barton Haynes, M.D., of Duke University, Durham, N.C., was established in 2005 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
CHAVIs host genetics team, led by David Goldstein, Ph.D., also of Duke University, included scientists from several European countries and Australia who formed a consortium, EuroCHAVI, to perform this study. The investigators identified three gene variants, two of which are linked to an infected persons ability to control HIV viral load and a third that is implicated in disease progression to AIDS. The research is being published by Science on the Science Express Web site on Thursday, July 19.
CHAVI is designed to foster collaborative research to overcome roadblocks that have impeded HIV vaccine development, says NIAID Director Anthony S. Fauci, M.D. The insights into genetic factors influencing host control of HIV revealed by this work exemplify the power of such collective investigations.
Genome-wide association studies aim to identify genetic variations among people that can be tied to variations in disease susceptibility. Recent genome-wide association studies have found genetic markers linked to increased risk of such ailments as diabetes, cancer and heart disease. The CHAVI investigators are the first to apply genome-wide association techniques to an infectious disease.
People vary greatly in thei
Contact: Anne A. Oplinger
NIH/National Institute of Allergy and Infectious Diseases